Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease

AL01811 is a preclinical selective GBA2 inhibitor with first-in-class potential [...]